Clinically, high NMT1 expression is significantly associated with poor prognosis in patients with HNSCC, and NMT1 colocalizes with HIF1α/PD-L1, suggesting its potential as a combined biomarker. This evidence concerns the gene HIF1A and head and neck squamous cell carcinoma.